Added Value of Interim FDG PET/CT in Resolving PSA-PSMA Discordance during PSMA-targeted Radioligand Therapy. Kassas M, Artigas C, Refalo N, Mallia A, et al. Clin Nucl Med 2026;51:191-193.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kassas M, Artigas C, Refalo N, Mallia A, et al. Added Value of Interim FDG PET/CT in Resolving PSA-PSMA Discordance during PSMA-targeted Radioligand Therapy. Clin Nucl Med 2026;51:191-193.
PMID: 41490309